查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961264

老年失智症症治療市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、最終用戶、地區和競爭對手分類，2021-2031年

Alzheimer's Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球阿茲海默症治療市場預計將從 2025 年的 49.2 億美元成長到 2031 年的 77.7 億美元，複合年成長率為 7.92%。

阿茲海默症治療藥物是指一系列旨在改善該疾病病理或緩解相關症狀的藥物。該市場的成長主要受全球人口老化加劇以及由此導致的失智症盛行率上升的驅動，這使得對有效臨床干預措施的需求變得特別迫切。此外，該疾病帶來的巨大經濟負擔也推動了醫療需求並刺激了研究投入。根據阿茲海默症協會預測，到2025年，美國阿茲海默症和其他失智症患者的總費用預計將達到3,840億美元。

市場概覽
預測期 2027-2031
市場規模：2025年 49.2億美元
市場規模：2031年 77.7億美元
複合年成長率：2026-2031年 7.92%
成長最快的細分市場 膽鹼酯酶抑制劑
最大的市場 北美洲

儘管存在這些成長要素，但由於候選藥物在臨床試驗中的高脫落率，該領域仍面臨許多重大挑戰。疾病複雜的生物學特性導致科學研究失敗頻傳，進而造成監管核准延遲和研發成本飆升。這種臨床試驗屢屢受挫的趨勢，為製藥研發公司和投資者創造了不穩定的環境，嚴重阻礙了創新療法在全球市場的快速擴張和商業化。

市場促進因素

全球人口老化及其導致的疾病盛行率上升是阿茲海默症治療領域發展的主要驅動力。隨著全球平均壽命的延長，神經退化性疾病的發生率激增，對有效藥物介入的需求也日益迫切。這種人口結構的變化迫使醫療衛生系統引入能夠控制症狀並延緩疾病進展的治療方法。根據世界衛生組織（世衛組織）2024年3月發布的《失智症》概況介紹，目前全球有超過5,500萬人患有失智症，每年新增病例約1,000萬例。如此迅速成長的患者群體需要廣泛推廣治療方法，這不僅能確保研發公司的持續收入，還能推動失智症護理在全球衛生政策中佔據戰略優先地位。

同時，新型疾病修正治療的商業化和臨床研發管線的擴展正對市場產生顯著影響。製藥公司正日益將研發重心從對症治療轉向靶向潛在的疾病機制，例如BETA-澱粉樣蛋白斑塊，這提振了投資者信心並推動了新產品的上市。公共部門為加速藥物發現的投資，為此創新發展軌跡提供了強而有力的支持。例如，根據美國國家老化研究所 (NIA) 的報告，2024 年聯邦預算中新增了1 億美元用於阿茲海默症及相關失智症的研究。這項研究規模龐大，阿茲海默症協會 2024 年 5 月的報告顯示，目前有 164 種藥物正在進行臨床試驗，顯示治療方案的未來前景廣闊。

市場挑戰

臨床試驗中候選藥物的高脫落率是全球阿茲海默症治療市場成長的一大障礙。這項挑戰主要源自於疾病複雜的生物學特性，在從臨床前模型過渡到人體試驗的過程中，常常會出現意想不到的療效不佳。當前景看好的候選藥物在後期臨床試驗中失敗時，研發公司將遭受巨額損失，並面臨漫長的研發週期。這種反覆出現的模式造成了不穩定的環境，阻礙了持續的資本投入，迫使製藥公司採取極其保守的策略，最終減緩了創新步伐和新產品的市場進入速度。

這些臨床試驗挫折的直接後果是，具有商業性可行性的治療方法研發管線有限，這限制了該領域的產生收入機會。研究成果與監管核准之間的差距依然顯著，造成了供應瓶頸。根據阿茲海默症協會預測，到2024年，將有164種阿茲海默症藥物進入臨床試驗階段，但由於開發平臺固有的高失敗率，儘管研究工作正在積極開展，但預計只有少數藥物能夠克服研發障礙，真正實現市場擴張。

市場趨勢

血液生物標記的應用正在改變患者分層方式，取代了PET掃描和腦脊髓液分析等昂貴且有創的診斷方法。這種向更容易取得的血漿診斷工具的轉變將克服臨床試驗中患者招募緩慢這一重大瓶頸，從而實現大規模的疾病早期檢測，這對於及時用藥至關重要。診斷準確性的提高將有助於快速識別適合疾病修正治療的患者，直接影響市場滲透率和保險報銷模式。根據阿茲海默症協會2024年7月發布的新聞稿，一項關鍵研究表明，一種名為APS2的特定血液檢測在識別阿茲海默症病理方面具有約90%的準確率，顯著優於使用傳統評估方法的基層醫療醫生63%的準確率。

同時，隨著人們對神經退化疾病代謝因子的認知不斷提高，製藥業正在進行一項策略性轉變，即重新利用GLP-1促效劑及其代謝物。製藥公司正在積極研究這些核准用於治療糖尿病和肥胖症的藥物，探索其在傳統澱粉樣蛋白標靶治療之外，發揮減輕神經發炎和神經保護作用的潛力。這一趨勢代表了一種經濟有效的途徑，可以透過利用安全性已驗證的藥物，實現治療方案的多元化，並降低新藥研發的風險。根據2024年12月發表在BioSpace上的一篇報導，一項真實世界臨床研究表明，與未接受Semaglutide肽治療的患者相比，接受索瑪魯肽治療的2型糖尿病患者患阿茲海默症的風險降低了40%至70%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：老年失智症症治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品種類（膽鹼酯酶抑制劑{多奈哌齊、Galantamine、Rivastigmine}、NMDA受體拮抗劑、複方藥物、正在研藥物）
    • 依最終用戶（醫院藥局、零售藥局、電子商務）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美老年失智症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲老年失智症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區老年失智症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲老年失智症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美老年失智症症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球老年失智症治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Eisai Co., Ltd.
  • Novartis AG
  • AbbVie Inc.（Allergan Plc.）
  • Adamas Pharmaceuticals, Inc.
  • H. Lundbeck A/S
  • Biogen Inc.
  • AC Immune SA
  • F. Hoffmann La Roche Ltd.
  • Daiichi Sankyo Company Limited
  • Johnson & Johnson

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23412

The Global Alzheimer's Therapeutics Market is projected to expand from USD 4.92 Billion in 2025 to USD 7.77 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.92%. Alzheimer's therapeutics consist of pharmaceutical agents developed to modify the disease's pathology or alleviate symptoms associated with the condition. The market is primarily propelled by the growing global elderly population and the corresponding increase in dementia prevalence, which creates a critical need for effective clinical interventions. Additionally, the substantial economic strain caused by the disease fuels the demand for medical treatments and stimulates research investment; according to the Alzheimer's Association, the total cost of care for individuals with Alzheimer's and other dementias in the United States is expected to reach $384 billion in 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.92 Billion
Market Size 2031USD 7.77 Billion
CAGR 2026-20317.92%
Fastest Growing SegmentCholinesterase Inhibitors
Largest MarketNorth America

Despite these growth factors, the sector encounters a major obstacle due to the high attrition rate of drug candidates during clinical trials. The complex biology of the disease frequently results in scientific failures that delay regulatory approval and escalate development costs. This trend of clinical setbacks creates a precarious landscape for pharmaceutical developers and investors, significantly hindering the rapid expansion and commercialization of innovative therapeutic solutions in the global market.

Market Driver

The expanding global geriatric population and the resulting rise in disease prevalence act as the primary catalysts for the growth of the Alzheimer's therapeutics sector. As life expectancy increases worldwide, the incidence of neurodegenerative conditions is surging, generating an urgent and sustained demand for effective pharmaceutical interventions. This demographic shift exerts immense pressure on healthcare systems to adopt treatments capable of managing symptoms or slowing disease progression. According to a March 2024 'Dementia' fact sheet by the World Health Organization, there are currently over 55 million people living with dementia globally, with nearly 10 million new cases arising annually. This rapidly growing patient base requires the widespread availability of therapeutic agents, ensuring continuous revenue for developers and driving the strategic prioritization of dementia care in global health policies.

Simultaneously, the market is significantly influenced by the commercialization of new disease-modifying therapies and the broadening of the clinical pipeline. Pharmaceutical companies are increasingly shifting focus from symptomatic relief to targeting underlying disease mechanisms, such as amyloid-beta plaques, which fosters renewed investor confidence and drives product launches. This innovation trajectory is heavily supported by public sector investment designed to accelerate discovery; for instance, the National Institute on Aging reported that 2024 federal appropriations provided a $100 million increase for Alzheimer's and related dementias research. The scale of this research is extensive, with the Alzheimer's Association's May 2024 report noting 164 agents currently in clinical trials, indicating a robust future for therapeutic options.

Market Challenge

The high attrition rate of drug candidates during clinical trials serves as a significant barrier to the growth of the global Alzheimer's therapeutics market. This challenge arises largely from the complex biological nature of the disease, which often results in unexpected efficacy failures as pharmaceutical agents move from preclinical models to human testing. When promising candidates fail in late-stage trials, developers suffer massive financial losses and face extended development timelines. This recurring pattern creates a volatile environment that discourages sustained capital investment and compels pharmaceutical companies to adopt highly conservative strategies, ultimately slowing the pace of innovation and the market entry of new products.

The direct result of these clinical setbacks is a restricted pipeline of commercially viable treatments, which limits revenue generation opportunities for the sector. The disparity between research efforts and successful regulatory approvals remains significant, creating a supply bottleneck. Although the Alzheimer's Association reported 164 agents in clinical trials for Alzheimer's disease in 2024, the high failure rate inherent to this pipeline means that despite the volume of active research, only a small fraction of these agents are likely to overcome development hurdles and contribute to actual market expansion.

Market Trends

The adoption of blood-based biomarkers is transforming patient stratification by replacing expensive and invasive diagnostic methods such as PET scans and cerebrospinal fluid analysis. This shift toward accessible plasma diagnostic tools resolves the critical bottleneck of slow clinical trial recruitment and enables earlier disease detection on a population scale, which is vital for the timely administration of therapeutics. Enhanced diagnostic precision allows for the rapid identification of suitable candidates for disease-modifying therapies, directly influencing market uptake and payer reimbursement models. According to a July 2024 press release by the Alzheimer's Association, a pivotal study demonstrated that a specific blood test known as APS2 was approximately 90% accurate in identifying Alzheimer's pathology, significantly outperforming primary care physicians who were only 63% accurate using traditional evaluation methods.

Concurrently, the sector is witnessing a strategic pivot toward repurposing GLP-1 agonists and metabolic agents, driven by the increasing recognition of the metabolic components of neurodegeneration. Pharmaceutical developers are actively investigating these agents, originally approved for diabetes and obesity, for their potential to reduce neuroinflammation and offer neuroprotection beyond traditional amyloid-targeting mechanisms. This trend represents a cost-efficient pathway to diversify therapeutic portfolios and mitigate the risks associated with novel drug development by leveraging agents with established safety profiles. According to a December 2024 BioSpace article, a real-world study indicated that patients with type 2 diabetes prescribed semaglutide showed a 40% to 70% reduction in the risk of being diagnosed with Alzheimer's disease compared to unexposed patient groups.

Key Market Players

  • Eisai Co., Ltd.
  • Novartis AG
  • AbbVie Inc. (Allergan Plc.)
  • Adamas Pharmaceuticals, Inc.
  • H. Lundbeck A/S
  • Biogen Inc.
  • AC Immune SA
  • F. Hoffmann La Roche Ltd.
  • Daiichi Sankyo Company Limited
  • Johnson & Johnson

Report Scope

In this report, the Global Alzheimer's Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alzheimer's Therapeutics Market, By Product Type

  • Cholinesterase Inhibitors {Donepezil, Galantamine, Rivastigmine}
  • NMDA Receptor Antagonist
  • Combination Drugs
  • Pipeline Drugs

Alzheimer's Therapeutics Market, By End User

  • Hospital Pharmacy
  • Retail Pharmacy
  • E-commerce

Alzheimer's Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alzheimer's Therapeutics Market.

Available Customizations:

Global Alzheimer's Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alzheimer's Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Cholinesterase Inhibitors {Donepezil, Galantamine, Rivastigmine}, NMDA Receptor Antagonist, Combination Drugs, Pipeline Drugs)
    • 5.2.2. By End User (Hospital Pharmacy, Retail Pharmacy, E-commerce)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Alzheimer's Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Alzheimer's Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Alzheimer's Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Alzheimer's Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By End User

7. Europe Alzheimer's Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Alzheimer's Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Alzheimer's Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Alzheimer's Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Alzheimer's Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Alzheimer's Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Alzheimer's Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Alzheimer's Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Alzheimer's Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Alzheimer's Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Alzheimer's Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Alzheimer's Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Alzheimer's Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Alzheimer's Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Alzheimer's Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Alzheimer's Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By End User

10. South America Alzheimer's Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Alzheimer's Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Alzheimer's Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Alzheimer's Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Alzheimer's Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eisai Co., Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. AbbVie Inc. (Allergan Plc.)
  • 15.4. Adamas Pharmaceuticals, Inc.
  • 15.5. H. Lundbeck A/S
  • 15.6. Biogen Inc.
  • 15.7. AC Immune SA
  • 15.8. F. Hoffmann La Roche Ltd.
  • 15.9. Daiichi Sankyo Company Limited
  • 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer